Video

Q&A With Robert Lisak from Wayne State University School of Medicine: New Research and Treatments Highlight CMSC Agenda

Author(s):

It was a busy few days in Indianapolis for the Consortium of Multiple Sclerosis Centers. The annual meeting highlighted not only new treatments currently available to patients but also work coming down the pipeline for future options.

It was a busy few days in Indianapolis for the Consortium of Multiple Sclerosis Centers. The annual meeting highlighted not only new treatments currently available to patients but also work coming down the pipeline for future options.

Robert P. Lisak, MD, from the Wayne State University School of Medicine said advancements in the treatment of the relapsing form of the condition, and new research about the progressive form made for an informative session. Lisak, who also serves as President of the Consortium of Multiple Sclerosis Centers said he was also encouraged to see many new attendees at the event and the contributions made by first time people at the annual conference.

Related Videos
Caroline Piatek, MD: High HCRU, Patient Concerns Highlight Great Unmet Need in wAIHA
Steven W. Pipe, MD: Supporting Gene Therapy Implementation for Hemophilia
Corinna L. Schultz, MD: Improving Sickle Cell Trait Documentation in Infancy
Sibgha Zaheer, MD: Determining Washout Period With Fitusiran, Emicizumab Transition for Hemophilia
Pavan K. (Tem) Bendapudi, MD: Large-Scale Analyses Elucidate Genetic Risk of Thrombosis
Seema Rani, MD: Examining Sleep Health in Youth With SCD
Daniel Wang: A More Appropriate Ferritin Threshold is Cost-Effective for Iron Deficiency Screening
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
© 2025 MJH Life Sciences

All rights reserved.